Sorin Biomedica, the Italian biomedical concern which is part of the Fiat-controlled Snia group, has announced gross profits of 58 billion lire ($36.3 million) for the first six months of 1993. At group level, this amounts to more than double the 19 billion lire gross profit reported in the same year-earlier period. The strong increase reflects in part non-recurrent profits from sale of assets, amounting to around 137 billion lire ($85.9 million).
Group consolidated operating profit remained stable at 44 billion lire, from 43 billion lire in the first half of 1992. Group sales climbed considerably to 406 billion lire ($254.5 million), up 23% on the like, year-earlier period. Exports amounted to 63% of total turnover, up from 57% a year earlier. Indebtment by the group fell from 396 billion lire in the first half of 1992 to 275 billion lire.
Investment in R&D amounted to 46 billion lire at group level, or 11.3% of sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze